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The use of microbicides is a promising approach for the prevention of HIV-1 transmission. Unfortunately,
various candidates failed in clinical trials. In some cases, the candidate microbicide even resulted in enhanced
virus transmission. Therefore, there is an urgent need to develop more predictive preclinical strategies to
anticipate the in vivo efficiency/toxicity rate, including in vitro assays that evaluate effects on epithelial integrity
and inflammation. The present study aims to identify potential safety issues concerning the use of microbicides
and excipients commonly used in vaginal microbicide preparations. The toxicities of various active pharma-
ceutical ingredients (APIs; TMC-120, UC-781, tenofovir [PMPA], PRO-2000, and glycerol monolaurate
[GML]) and excipients (preservatives, cosolvents, surfactants, and cyclodextrins) were evaluated using an in
vitro dual-chamber model and uterine cervical explants. Epithelial viability and permeation of fluorescent
virus-sized beads, as well as induction of interleukin-8 (IL-8; as a sensitive marker of an inflammatory
response), were assessed. Surprisingly, cell viability and epithelial layer integrity were compromised by most
excipients at concentrations near the typical concentration used in vaginal gels, and a significant increase in the
production of IL-8 was observed at subtoxic concentrations. Within the APIs, TMC-120, UC-781, and PMPA showed
higher selectivity indices than PRO-2000 and GML. In conclusion, identification of safety issues concerning the use
of pharmaceutical excipients could help to formulate less toxic vaginal microbicide preparations.
There is an urgent need to develop safe, effective, and
acceptable vaginal products for the prevention of sexually
transmitted infections (STIs), including HIV-1 infections.
Since barrier methods, such as male and female condoms,
are, unfortunately, not yet sufficiently accepted, efficacious vac-
cines and topical microbicides are needed (4, 6, 8). The vagina
has been explored as a suitable site for delivery of drugs used
for the treatment of local, female-specific infections, such as
vaginitis, bacterial vaginosis, and candidiasis (16, 39). Vaginally
administered formulations are also being developed to provide
protection against various STIs, including HIV-1 infections.
Unfortunately, in the past few years, several phase IIB/III clinical
trials of candidate microbicides (i.e., nonoxynol-9 [N-9], cellulose
sulfate [CS], Savvy [C31G], a carrageenan-based vaginal gel
[Carraguard], and a vaginal gel containing a polyanionic entry
inhibitor [PRO-2000]) resulted in rather disappointing find-
ings, showing either no significant reduction or even an in-
crease in HIV-1 transmission (10, 20, 29, 32, 35).
Various classes of antiretroviral compounds (ARVs) with
activities against HIV are available, and new drugs are still
being developed. Their chemical diversity requires the use of
different and often compound-specific formulation strategies
to make them suitable for use as effective microbicides. Deliv-
ery strategies must (i) ensure delivery of an effective concen-
tration, (ii) maintain the active form in the female genital tract,
and (iii) be nontoxic and encompass gels, tablets, supposito-
ries, films, and rings (17). Excipients are inactive ingredients
needed for efficient in vivo delivery of the active pharmaceu-
tical ingredient (APIs) (16). They ensure specific properties of
the formulation, including retention and spreading (e.g., vis-
cosity enhancers), stability (e.g., preservatives and humec-
tants), and solubilizing capacity (e.g., cosolvents, surfactants,
and cyclodextrins).
Like any other pharmaceutical drug, candidate microbicides
are subject to several stages of efficacy and safety testing before
proceeding to phase III clinical trials. Preclinical safety testing
includes the assessment of toxicity in cell- and tissue-based
assays (including assays with epithelial cell lines, peripheral
blood mononuclear cells, primary epithelial cells, and cervical
explants). Besides these in vitro and ex vivo models, models
involving small animals (mice and rabbits) and nonhuman pri-
mates are currently used for safety screening of microbicide
candidates. However, there are various ethical and practical
issues, such as the increasing number of candidate microbi-
cides and formulation options, the suboptimal reproducibility
of the vaginal irritation model, the limited availability of non-
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human primates, and the differences between the animal and
human physiology.
In order to reduce the failure rate of microbicide formula-
tions in animal and clinical testing, better in vitro or ex vivo
screening tools to identify potential safety issues are needed.
Obviously, both the APIs and pharmaceutical excipients used
in the formulations may have detrimental effects on the cervi-
covaginal mucosa, from causing a local inflammation (with
influx of potential HIV target cells) to impairing the epithelial
barriers, potentially leading to an increased risk of HIV acqui-
sition. While the toxicity profiles of microbicide candidate
APIs are already being assessed in in vitro screening assays
(cell-based assays, tissue explants), this is not the case for
excipients. Selection of excipients is mainly based on their
functionality and, if available, data on previous use in vaginal
formulations, as can be found in the FDA list of inactive
ingredients (9). The latter might be a good reference to use to
judge the safety of vaginal preparations intended for short-term
use (such as products for the treatment of local infections) but
may be less well adapted for the evaluation of products intended
for long-term repeated use (such as contraceptives, hygiene prod-
ucts, and microbicides). Currently, safety issues due to excipients
may be suspected only during animal testing of complete formu-
lations. Therefore, in vitro safety screening of excipients in early
development would be of great assistance to scientists in compos-
ing appropriate microbicide formulations.
In the present study, a recently described in vitro dual-cham-
ber model (15) was applied as a screening tool to detect po-
tential safety issues for candidate microbicides and pharma-
ceutical excipients. Their effects on the viability of a variety of
genital epithelial cell lines as well as cervical tissue explants
were assessed. In addition, the integrity of the epithelial layer
as well as induction of interleukin-8 (IL-8) production by ep-
ithelial cells was evaluated. Various candidate microbicides
(TMC-120, UC-781, tenofovir [PMPA], PRO-2000, and glyc-
erol monolaurate [GML]) and various classes of excipients
(preservatives, cosolvents, surfactants, and cyclodextrins) were
evaluated in these assays.
MATERIALS AND METHODS
Epithelial cells. The cell lines HEC-1A, SiHa, and CaSki were obtained from
the American Type Culture Collection (ATCC-LGC Promochem, Teddington,
United Kingdom). The uterine HEC-1A cell line originates from a human
endometrial adenocarcinoma (23). SiHa cells originate from a uterine cervical
carcinoma and have been reported to contain one to two copies of an integrated
human papillomavirus type 16 (HPV-16) genome per cell (2). CasKi is a uterine
cervical carcinoma cell line containing an integrated HPV-16 genome at about
600 copies per cell, as well as sequences related to HPV-18 (1).
HEC-1A cells were cultured in McCoy’s 5A modified medium (Invitrogen,
Merelbeke, Belgium) supplemented with 100 U/ml penicillin, 100 g/ml strep-
tomycin, and 10% fetal bovine serum (FBS), further referred to as McCoy’s
complete medium. SiHa and CaSki cells were cultured in Dulbecco modified
Eagle medium (DMEM)–F-12 medium (Invitrogen) supplemented with penicil-
lin (100 U/ml), streptomycin (100 g/ml), and 10% FBS and is further referred
to as complete medium.
Cervical tissue explants. Cervical tissue was obtained from premenopausal
women undergoing planned therapeutic hysterectomy at Ghent University Hos-
pital (written consent was obtained from all tissue donors, according to the local
research ethics committee). Cervical explants comprising both epithelial and
stromal tissues (diameter, 3 mm) were cultured in 96-well flat-bottomed tissue
culture plates in RPMI with 10% FBS (19).
Transwell dual-chamber system. HTS Transwell-96 permeable supports
(Corning Costar Corp., Cambridge, MA) developed for high-throughput screen-
ing applications were used. The apical chamber of a dual-chamber Transwell
system (Fig. 1) with a growth area of 0.143 cm2 (pore size, 3.0 m) was coated
with 200 ng/ml of laminin (Sigma-Aldrich, St. Louis, MO) and air dried. One
hundred thousand HEC-1A cells (in 100 l) were cultured in the apical chamber.
The basal chamber contained 150 l of McCoy’s medium. The cells were cul-
tured for 3 days, and the medium in the basal chamber was refreshed on day 2
of the culture.
APIs. The nonnucleoside reverse transcriptase inhibitor (NNRTI) UC-781 was
kindly provided by A. Van Aerschot, Rega Institute, Leuven, Belgium, whereas
the NNRTI TMC-120 (dapivirine) was kindly donated by Tibotec BVBA,
Mechelen, Belgium. Stock solutions of these hydrophobic compounds were pre-
pared by dissolution in dimethyl sulfoxide (DMSO) at a concentration of 100
mM. To avoid DMSO-induced toxicity, stock solutions were diluted at least
1,000-fold in culture medium before use. Stock solutions of the nucleotide
reverse transcriptase inhibitor (NRTI) PMPA (tenofovir; kindly provided by J.
Balzarini, Rega Institute, Leuven, Belgium), GML (monomuls 90-L 12; donated
by Cognis Corporation Care Chemicals, Hoofddorp, Netherlands), PRO-2000
(kindly provided by A. Profy, Indevus Pharmaceuticals, Inc., Lexington, MA),
and N-9 (Tergitol; Sigma-Aldrich, Bornem, Belgium) were prepared in phos-
phate-buffered saline (PBS; BioWhittaker, Verviers, Belgium).
Pharmaceutical excipients. Excipients belonging to various classes were used
(Table 1), including five preservatives, consisting of methylparaben, propylpara-
ben, and sorbic acid (Sigma-Aldrich, St. Louis, MO), benzyl alcohol (Acros
Organics, Geel, Belgium), and benzalkonium chloride (Certa, Braine-L’Alleud,
Belgium); five cosolvents, consisting of ethanol, glycerin, polyethylene glycol
1000 (PEG 1000; Sigma-Aldrich, St. Louis, MO), polyethylene glycol 400 (PEG
400; Acros Organics, Geel, Belgium), and propylene glycol (PG; Certa, Braine-
L’Alleud, Belgium); four surfactants, consisting of Cremophor EL (Sigma-Al-
drich, St. Louis, MO), D--tocopheryl polyethylene glycol 1000 succinate (TPGS
1000; Eastman Chemical Company, Kingsport, TN), polysorbate 80 (Tween 80;
FIG. 1. Schematic representation of the in vitro models used to evaluate the toxicities of various microbicide candidates and excipients.
(A) Nonpolarized exposure setup. Epithelial cells (HEC-1A, CaSki, or SiHa cells) were cultured in 96-well flat-bottomed culture plates.
(B) Polarized exposure setup. Assays were performed in a dual-chamber model that consists of an apical chamber (Transwell) and a basal chamber.
On top of the permeable membrane, HEC-1A cells were cultured and formed a confluent epithelial layer. In this setup, only the apical side of the
HEC-1A layer was exposed to the APIs/excipients. (C) Cervical tissue explant. Cervical explants were cultured in 96-well flat-bottomed culture
plates and exposed to the APIs/excipients in a nonpolarized fashion.
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Certa, Braine-L’Alleud, Belgium), and sodium lauryl sulfate (SLS; Merck,
Darmstadt, Germany); and seven cyclodextrins, consisting of -cyclodextrin (-
CD), hydroxypropyl--cyclodextrin (HP--CD), hydroxypropyl--cyclodextrin
(HP--CD), and dimethyl--cyclodextrin (DM--CD) (Sigma-Aldrich, St. Louis,
MO), -cyclodextrin (-CD; Roquette, Lestrem, France), -cyclodextrin hydrate
(-CD; Acros Organics, Geel, Belgium), and sulfobutyl ether--cyclodextrin
(SBE--CD; Captisol; CyDex Pharmaceuticals Inc., Lenexa, KS). Serial dilutions
of these excipients were prepared in complete medium.
Evaluation of toxicity. The tissue/cell viability upon exposure to the various
APIs and excipients was assessed in three different setups: in nonpolarized and
polarized exposures of epithelial cell lines and a nonpolarized exposure in cer-
vical tissue explants. Cytotoxicity was assessed using an enhanced colorimetric
cell proliferation/viability assay, performed with a water-soluble tetrazolium-1
(WST-1) cell proliferation kit, according to the manufacturer’s instructions
(Roche, Vilvoorde, Belgium). The assay is based on the cleavage of the tetra-
zolium salt WST-1 ({4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-
benzene disulfonate}) to a formazan dye by a complex cellular mechanism. This
bioreduction is largely dependent on the glycolytic production of NAD(P)H in
viable cells. Therefore, the amount of formazan dye formed directly correlates to
the number of viable cells in the culture and can be quantified by measuring the
absorbance at 450 nm in a multiwell plate reader. The greater the number of
viable, cells, the greater the amount of formazan dye produced following the
addition of WST-1.
Nonpolarized exposure to APIs/excipients. Twenty-five thousand HEC-1A,
CaSki, or SiHa cells were seeded in 96-well plates and cultured for 3 days.
Afterwards, a serial dilution of an API/excipient was added to the epithelial cells
and the mixture was incubated for 24 h. After this exposure, the cells were
washed and WST-1 was added. Cell viability was quantified 1 h later by analysis
on a microplate reader (Bio-Rad, Tokyo, Japan) at 450 nm. The calculated
percentage of viable cells compared to the number of untreated control cells was
plotted against the compound concentration, and linear regression analysis was
performed using Prism (version 5.02) software for Windows (GraphPad Soft-
ware, San Diego, CA) to calculate the 50% cytotoxic concentration (CC50).
Polarized exposure to APIs/excipients. One hundred thousand HEC-1A cells
were grown to confluence on HTS Transwell permeable supports. On day 3 of
the culture, the apical side of the epithelial layer was exposed to a serial dilution
of one of the various APIs or excipients in complete medium for 24 h. The basal
chamber contained McCoy’s complete medium during the 24-h exposure. Sub-
sequently, the API/excipient was removed, washed once, and replaced by
McCoy’s complete medium and the WST-1 substrate was added to the basal
chamber for 2 h. The viability of the epithelial layer was assessed with the WST-1
assay, as described above.
Cervical tissue explant. Fresh cervical tissue was obtained after hysterectomy
at Ghent University Hospital. Explants were placed in 96-well flat-bottomed
tissue culture plates and treated with a serial dilution of an API/excipient for
24 h. Subsequently, the explants were washed once with culture medium, and
WST-1 substrate was added for 2 h. Tissue viability was assessed as described
above.
Permeability to fluorescent microspheres. One hundred thousand HEC-1A
cells were grown to confluence on HTS Transwell permeable supports. On day 3
of culture, the epithelial layer was exposed to a serial dilution of one of the
various APIs or excipients for 24 h. As a 100% toxic control, HEC-1A cells were
treated with 1% N-9. Subsequently, the excipient was removed, the cells were
washed once, and 100 l of a 1/20 dilution of fluorescent microspheres (Fluo-
Spheres sulfate microspheres; diameter, 0.1 m; yellow-green fluorescence [505/
515 nm]; 2% solids; Molecular Probes Europe NV, Leiden, Netherlands) was
added on top of the epithelial layer in the apical chamber, and the mixture was
incubated for another 24 h (37°C, 5% CO2). These microspheres have dimen-
sions similar to those of HIV-1 particles (i.e., a diameter of 100 nm). Afterwards,
the medium in the basal chamber was harvested; the presence of fluorescence
was assessed with a fluorometer (TriStar LB 941; Berthold Technologies GmbH,
Germany) and analyzed with MicroWin 2000 software. The percentage of beads
that crossed the treated epithelial layer compared to the number for the 1%
N-9-treated control was plotted against the compound concentration, and linear
regression analysis was performed using Prism (version 5.02) software for Win-
dows (GraphPad Software) to calculate the 50% toxic concentration (integrity)
(CC50, integrity).
Chemokine assay. One hundred thousand HEC-1A cells were cultured to
confluence on Transwell inserts (pore size, 3 m) for 3 days. Subsequently, the
apical side of the epithelial layer was exposed to a serial dilution of one of the
APIs or excipients in duplicate wells for 24 h. Culture supernatants were col-
lected from the basal compartment of the dual-chamber system at the end of the
24-h treatment period. The levels of IL-8 (CXCL8) in the culture supernatants
were quantified by a traditional colorimetric enzyme-linked immunosorbent as-
say (ELISA; RayBiotech IL-8 ELISA kit; Tebu Bio, Le Perray en Yvelines,
France).
Data processing and statistical analysis. Data were analyzed to produce
arithmetic or geometric means with standard deviations (SDs) using Microsoft
Excel or Prism (GraphPad Software) software. Linear regression analysis was
performed using GraphPad Prism software to calculate the 50% toxic concen-
tration in all assays. Analysis of variance (ANOVA) and the Student t test were
performed to determine the significance of the difference between sets of data.
Correlations between the different assays were calculated using the Spearman
rank correlation test.
TABLE 1. Excipients belonging to different classes evaluated in the present study
Product Class TC(% wt/wt)a Use
b
Methylparaben Preservative 0.18 Parenteral, enteral, otic, ophthalmic, rectal, nasal, vaginal
Propylparaben Preservative 0.02 Parenteral, enteral, otic, ophthalmic, rectal, nasal, vaginal
Sorbic acid Preservative 0.05–0.2 Enteral, dermal, vaginal
Benzyl alcohol Preservative 2 Parenteral, enteral, otic, nasal, ophthalmic, vaginal, dermal
Benzalkonium chloride Preservative 0.01–0.02 Parenteral, nasal, otic, ophthalmic, vaginal
Ethanol Cosolvent 1–10 Parenteral, enteral, ophthalmic, dermal, vaginal
Glycerin Cosolvent/humectant 1–20 Parenteral, enteral, otic, dermal, nasal, ophthalmic, vaginal
Polyethylene glycol 400 Cosolvent 20 Parenteral, enteral, ophthalmic, dermal, vaginal, nasal
Polyethylene glycol 1000 Cosolvent 20 Enteral, dermal, vaginal
Propylene glycol Cosolvent 1–40 Parenteral, enteral, otic, nasal, ophthalmic, dermal, rectal, vaginal
Cremophor EL Surfactant 0.1–2 Parenteral, enteral, ophthalmic, dermal, vaginal
TPGS 1000 Surfactant 0.1–2 Enteral, ophthalmic, dermal
Polysorbate 80 (Tween 80) Surfactant 0.1–2 Parenteral, enteral, otic, nasal, ophthalmic, rectal, dermal, vaginal
Sodium lauryl sulfate Surfactant 0.1–2 Enteral, dermal, vaginal
Hydroxypropyl--cyclodextrin Cyclodextrin 2.5–20 Parenteral, enteral, ophthalmic, dermal, vaginal, nasal
-Cyclodextrin Cyclodextrin 0.5–10 Parenteral, enteral, ophthalmic, dermal, vaginal, nasal
-Cyclodextrin Cyclodextrin 0.5–10 Parenteral, enteral, ophthalmic, dermal, vaginal, nasal
-Cyclodextrin hydrate Cyclodextrin 0.5–10 Parenteral, enteral, ophthalmic, dermal, vaginal, nasal
Hydroxypropyl--cyclodextrin Cyclodextrin 0.5–40 Parenteral, enteral, ophthalmic, dermal, vaginal, nasal
Dimethyl--cyclodextrin Cyclodextrin 0.5–40 Parenteral, enteral, ophthalmic, dermal, vaginal, nasal
Sulfobutylether--cyclodextrin Cyclodextrin 0.5–40 Parenteral, enteral, ophthalmic, dermal, vaginal, nasal
a The typical concentration used in pharmaceutical formulations.
b The type of preparation in which the excipient is used elsewhere (9).
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RESULTS
In vitro systems to model the female genital mucosa. To
evaluate the effects of APIs and excipients on the female gen-
ital mucosa, various in vitro models were used (Fig. 1). In the
first model, a nonpolarized exposure setup, cells of three dif-
ferent cell lines, i.e., HEC-1A (endometrium), CaSki, and
SiHa (uterine cervix), were grown in 96-well culture plates and
exposed for 24 h to a serial dilution of one of the excipients.
Cell viability was assessed using the WST-1 assay. In the sec-
ond model, a polarized exposure setup, a confluent layer of
HEC-1A cells, impermeable for fluorescent beads (diameter,
100 nm, which is the size of an HIV-1 virion), was grown on
HTS Transwell inserts (15) and subsequently exposed to a
serial dilution of each excipient or API applied on the apical
side only for 24 h. This in vitro setup mimics the in vivo appli-
cation of a microbicide, where the luminal side of the vaginal
and uterine cervical epithelium is exposed to the microbicide.
Following this exposure and washing of the compound, the
viability of the cell layer was assessed using the WST-1 assay
and the epithelial integrity by measuring the leakage of fluo-
rescent microspheres into the basal compartment. Finally, the
third model consisted of fresh uterine cervical tissue biopsy
specimens containing both the epithelium and the underlying
stroma in a physiological architecture. Explant tissue was ex-
posed, in a nonpolarized fashion, to a serial dilution of one of
the APIs or excipients. This more complex ex vivo model,
which is widely used in the microbicide field to evaluate the
safety and activity of candidate microbicides, was used as a
comparative standard.
Toxicity profiles of candidate microbicides in the various
assays. The viability of HEC-1A epithelial cells and cervical
tissue was assessed after a nonpolarized exposure to serial
dilutions of five candidate microbicides (TMC-120, UC-781,
PMPA, PRO-2000, and GML) and a compound that has been
clearly associated with an increased risk of HIV acquisition,
i.e., N-9. In addition, the viability and integrity of the HEC-1A
epithelial layer were assessed following a polarized exposure to
the APIs. In Fig. 2, dose-response curves and the resulting
FIG. 2. Toxicity profiles of various candidate microbicides (APIs). HEC-1A cells were cultured in 96-well culture plates (nonpolarized
exposure) and HTS Transwell inserts (polarized exposure) and exposed to the indicated microbicides (TMC-120, UC-781, PMPA, GML,
PRO-2000, and N-9). Toxicity toward HEC-1A epithelial cells and cervical tissue was assessed using WST-1. A change in epithelial layer integrity
was assessed using fluorescent microspheres. The viability of the HEC-1A epithelial layer in the nonpolarized exposure setup (solid circles), the
viability of the tissue explants in the nonpolarized exposure setup (solid triangles), and the viability of the HEC-1A epithelial layer in the polarized
exposure setup (open circles) compared to the viability of an untreated control (left y axis) are shown. The open triangles show the permeation
of beads through the HEC-1A epithelial layer in the polarized exposure setup compared to the results for a 1% N-9-treated control (right y axis).
Results are means  standard deviations from at least 2 independent experiments in which each condition was tested in triplicate.
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half-maximal cytotoxic concentrations (CC50s) are shown. In
vitro anti-HIV half-maximal effective concentrations (EC50s)
were added to allow interpretation of the toxicity data. The
NNRTI TMC-120 has an EC50 of about 0.003 M in a den-
dritic cell/T-cell coculture model (34) and had a CC50 of 35 M
(selectivity index [SI], 	11,666) in the nonpolarized exposure
setup. Remarkably, no cytotoxicity or decreased epithelial
layer integrity was observed in the polarized exposure of
HEC-1A cell layers to up to 100 M (SI, 	33,000), but some
cytotoxicity was evident in the cervical explant model at 100
M. Higher concentrations were not tested due to solubility
issues. The NNRTI UC-781 (EC50, 0.01 M in a dendritic
cell/T-cell coculture model) and the NRTI PMPA (EC50, 1.5
M in the same model) (34) displayed no cytotoxicity at the
evaluated concentrations (CC50s, 	100 M [SI, 	10,000] and
	1,000 M [SI, 	666], respectively) in all assays. PRO-2000, a
polyanionic entry inhibitor (EC50, 2 M in a dendritic cell/
T-cell coculture model) (unpublished data), displayed lower
SIs, showing a CC50 of 88 M (SI, 44) in the nonpolarized
exposure setup, whereas in the polarized exposure setup, a
reduced viability was observed at 300 M (CC50, 	1,000 M
[SI, 	500]). Nevertheless, the epithelial integrity was lost,
showing a CC50, integrity of 260 M (SI, 130), and a CC50 of 458
M (SI, 229) was observed in the cervical explant model. Next,
GML, which has an effective concentration against HIV of
364 M (31), showed a CC50 of 835 M (SI, 
2) in the
nonpolarized exposure setup and a CC50 of 2,300 M (SI, 
6)
in the polarized HEC-1A cell exposure setup. The epithelial
integrity toward microspheres was impaired starting at 547 M
GML, with the CC50, integrity being 1,319 M (SI, 
4). In the
cervical explant model, it showed a CC50 of 1,746 M (SI, 
5).
Finally, N-9 (EC50s, 0.0032 to 0.0081 M [40]), which was used
as a control, showed a CC50 of 0.01 M (SI, 1) in the nonpo-
larized exposure setup, a CC50 of 0.076 M (SI, 10) in the
polarized exposure setup, and a CC50, integrity of 0.089 M (SI,
11) in the bead permeation assay. In the cervical explant
model, N-9 showed a CC50 of 0.016 M (SI, 2).
Preliminary comparison of toxicity profiles of the excipients
in various epithelial cell lines and assays. The safety of a
selection of excipients belonging to different classes (i.e., pre-
servatives, cosolvents, surfactants, and cyclodextrins) was eval-
uated in the nonpolarized cytotoxicity assays, using three dif-
ferent cell lines (HEC-1A, CaSki, and SiHa) and cervical
explants. In addition, both cytotoxicity and functional layer
integrity were assessed in the polarized setup with HEC-1A
cells. Epithelial cell and tissue cytotoxicities were measured
using the WST-1 assay, whereas epithelial layer integrity was
assessed in a bead permeation assay and compared to that
achieved with a 1% N-9-treated control. Results are shown in
Table 2.
Comparison of the sensitivities of the various epithelial cell
lines (HEC-1A, CaSki, and SiHa) to the toxic effects of the
excipients in the nonpolarized setup showed only a few, statis-
tically nonsignificant differences between the various cell lines
for all except one excipient (i.e., glycerin), which appeared to
be selectively less toxic toward HEC-1A cells (P 
 0.05,
ANOVA). Furthermore, the CC50 values obtained in the ex-
plant model were not significantly (P 	 0.05, t test) different
from the values obtained in the nonpolarized exposure setup
with HEC-1A cells for any of the excipients except glycerin and
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Cremophor EL. In contrast, the CC50 values obtained in the
polarized exposure setup analyzed either with the viability as-
say or with the bead permeation assay in general showed
higher CC50 values compared to those obtained in the nonpo-
larized exposure setup, with the difference being significant for
methylparaben, ethanol, polyethylene glycol 400, and polyeth-
ylene glycol 1000.
Toxicity rank order of various excipients. On the basis of
these preliminary results, toxicity testing was continued in
three assays, i.e., the two viability assays with the HEC-1A cell
line (the nonpolarized and polarized exposure setups) and the
epithelial layer integrity assay (the beads permeation assay).
Within each class of excipients, a rank order based on the
CC50 values relative to the typical concentration (TC) used for
clinical applications can be made (Table 3). Among the pre-
servatives, cell viability and epithelial layer integrity were com-
promised the most by benzalkonium chloride, benzyl alcohol,
and propylparaben but were compromised less by methylpara-
ben and sorbic acid, for which the toxic concentration was
higher than the TC, at least in the polarized setups. The tested
cosolvents also displayed toxicity at clinically used concentra-
tions, with ethanol and glycerin having better profiles than the
polyethylene and propylene glycols. All tested surfactants ex-
erted toxic effects at concentrations equal to or lower than the
typical concentration used in formulations: sodium lauryl sul-
fate  TPGS 1000 	 polysorbate 80 	 Cremophor EL (low
toxicity). Among the cyclodextrins, the following relative rank
order for toxicity was observed: dimethyl--CD	-CD, -CD	
-CD 	 hydroxypropyl--CD 	 sulfobutylether--CD 	 hy-
droxypropyl--CD (in fact, hydroxypropyl--CD was the only one
with relatively low toxicity).
The CC50 values for viability obtained in the polarized ex-
posure setup were higher than those obtained in the nonpo-
larized exposure setup for all compounds except glycerin. The
difference between the two assays was statistically significant
for methylparaben, benzyl alcohol, ethanol, the polyethylene and
propylene glycols, hydroxypropyl--CD, and sulfobutylether-
-CD (P
 0.05, t test). The CC50 values obtained in the polarized
WST-1 assay did not differ significantly from those obtained in the
microsphere permeation assay (CC50, integrity).
The Spearman rank correlation test was used to investigate
the possible correlations between the toxicity rankings in the
various assays. The excipient ranking of the polarized exposure
assay was significantly correlated with the rankings of the non-
polarized assay (correlation coefficient, 0.90; P
 0.001), of the
bead permeation assay (correlation coefficient, 0.97; P 

0.001), and with the tissue explant model (correlation coeffi-
cient, 0.70; P  0.043). The excipient ranking of the nonpo-
larized exposure assay was also correlated with the rankings of
the bead permeation assay (correlation coefficient, 0.91; P 

0.001) and with the tissue explant model (correlation coeffi-
cient, 0.91; P  0.001).
Production of interleukin-8. IL-8, a proinflammatory che-
mokine, was quantified by ELISA in culture supernatants col-
lected from the basal chamber of the dual-chamber system
containing a confluent HEC-1A epithelial layer that was
treated with either the APIs (Fig. 3A) or the various classes of
excipients (Fig. 3B to D). The treatment was performed in a
polarized way (apical side) for 24 h and at low concentrations,
since we previously showed that IL-8 production is a more
sensitive marker of toxicity than either viability or permeabil-
ity. Treatment with N-9, known to induce a proinflammatory
TABLE 3. CC50 values obtained in three assays with HEC-1A cells
a
Product Class TC(% wt/wt)
CC50 obtained in HEC-1A cells (% wt/wt)a
Nonpolarized
assay (WST-1)
Polarized assay
WST-1 Microspheres
Methylparaben Preservative 0.18 0.05 (0.04-0.06) 0.66 (0.58-0.72) 0.67 (0.58-0.85)
Propylparaben Preservative 0.02 0.03 (0.01–0.07) 0.07 (0.06–0.08) 0.07 (0.06–0.07)
Sorbic acid Preservative 0.05–0.2 0.58 (0.49–0.64) 1.22 (0.70–2.00) 0.86 (0.65–1.10)
Benzyl alcohol Preservative 2 0.13 (0.07–0.32) 0.66 (0.57–0.73) 0.87 (0.63–1.09)
Benzalkonium chloride Preservative 0.01–0.02 
0.001 (
0.001) 0.003 (0.002–0.003) 
0.001 (
0.001)
Ethanol Cosolvent 1–10 3.13 (2.42–3.70) 	30 (	30) 	30 (	30)
Glycerin Cosolvent/humectant 1–20 	20 (	20) 16.46 (10.87–19.74) 18.41 (17.48–19.49)
Polyethylene glycol 400 Cosolvent 20 6.71 (5.32–7.83) 23.52 (18.00–29.17) 15.20 (14.07–16.16)
Polyethylene glycol 1000 Cosolvent 20 9.30 (7.83–12.41) 23.99 (18.17–28.77) 18.01 (17.41–19.12)
Propylene glycol Cosolvent 1–40 11.19 (9.90–11.90) 16.18 (15.21–17.52) 23.21 (20.02–26.93)
Cremophor EL Surfactant 0.1–2 
0.5 (
 0.5) 2.19 (0.97–4.51) 1.92 (1.29–3.67)
TPGS 1000 Surfactant 0.1–2 
0.05 (
0.05) 
0.05 (
0.05) 
0.05 (
0.05)
Polysorbate 80 Surfactant 0.1–2 0.04 (0.03–0.07) 0.38 (0.22–0.58) 0.92 (0.57–1.29)
Sodium lauryl sulfate Surfactant 0.1–2 
0.05 (
0.05) 
0.05 (
0.05) 
0.05 (
0.05)
Hydroxypropyl--cyclodextrin Cyclodextrin 2.5–20 7.25 (6.22–8.00) 8.23 (8.02–8.58) 9.41 (7.85–12.38)
-Cyclodextrin Cyclodextrin 0.5–10 1.66 (1.05–2.47) 1.80 (0.86–2.52) 2.12 (2.00–2.38)
-Cyclodextrin Cyclodextrin 0.5–10 1.50 (1.12–2.61) 2.59 (2.16–2.85) 2.52 (2.27–2.97)
-Cyclodextrin hydrate Cyclodextrin 0.5–10 4.65 (2.37–6.99) 8.62 (6.57–10.71) 6.77 (5.19–8.91)
Hydroxypropyl--cyclodextrin Cyclodextrin 0.5–40 15.35 (12.05–21.00) 	40 (	40) 	40 (	40)
Dimethyl--cyclodextrin Cyclodextrin 0.5–40 0.15 (0.14–0.16) 0.19 (0.15–0.23) 0.21 (0.17–0.29)
Sulfobutylether--cyclodextrin Cyclodextrin 0.5–40 10.77 (9.41–11.84) 14.13 (13.13–14.78) 17.52 (15.67–20.77)
a The three assays comprised two cytotoxicity assays and one functional assay. The geometric means and ranges of three independent experiments performed in
triplicate wells are shown. The CC50 values in the nonpolarized and polarized assays reflect the concentration which reduces the cell viability to 50% compared to that
for the untreated control (measured using WST-1). The CC50 value in the microsphere permeation assays reflects the concentration which raises the permeation of
fluorescent microspheres to 50% of that for a 1% nonoxynol-9-treated control (100% toxicity).
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response (11, 12), showed a strong increase in the level of IL-8
production starting at 0.008 M (i.e., 10 times lower than the
CC50 in the polarized WST-1 assay). Higher concentrations of
N-9 induced a decrease in the level of IL-8 secretion, most
probably as a result of cell death. Treatments with UC-781 and
TMC-120 showed small increases in the level of IL-8 produc-
tion starting at 10 M. None of the APIs showed cytotoxicity
at 100 M in the polarized WST-1 assay, and only TMC-120
had a CC50 of 35 M in the nonpolarized WST-1 assay. PRO-
2000 increased the level of IL-8 production starting at 10 M
(10 times below that obtained in the nonpolarized WST-1 assay
and 	100 times below the polarized WST-1 assay CC50).
Rather remarkably, GML did not affect IL-8 production even
at a cytotoxic concentration. Among the preservatives, sorbic
acid and benzalkonium chloride treatments produced strong
increases in IL-8 secretion at 0.2% and 0.001%, respectively;
but methylparaben, propylparaben, and benzyl alcohol were
inactive in this regard and increased IL-8 secretion at up to 0.5
and 1%. Of the cosolvents, only glycerin and PEG 400 in-
creased the level of IL-8 secretion at 5% and 3%, respectively.
All surfactants induced a strong increase in IL-8 production
(Cremophor EL at 0.5%, polysorbate 80 at 0.5%, TPGS 1000
at 0.01%, and SLS at 0.005%). Finally, dimethyl--CD and
-CD increased IL-8 production at 0.5% and 5%, respectively
(Fig. 3).
Clearly, for some APIs (e.g., UC-781 and PRO-2000) and
some excipients (e.g., sorbic acid, glycerin, Cremophor EL,
polysorbate 80, and cyclodextrins), the IL-8 assay unveils a
presumed proinflammatory effect at concentrations that in-
duce no or limited cytotoxicity in viability or permeation as-
says. Conversely, other compounds (e.g., GML, the parabens,
and the polyethylene glycols) fail to induce IL-8 secretion at
any concentration used, whereas viability and permeation as-
says indicate clear toxic effects over a similar concentration
range.
DISCUSSION
The vaginal mucosa is commonly exposed to contraceptives,
feminine-care products, and drugs for the treatment of female-
specific conditions (16). Hence, irritation of epithelial surfaces
due to chemical insult remains a concern. For the prevention
of HIV infection, a safe and efficacious anti-HIV microbicide
is highly desirable but is not yet available. Recently, four phase
IIB/III trials of candidate microbicides (i.e., cellulose sulfate,
Savvy, Carraguard, and PRO-2000) showed no reduction or
even an increased risk of acquiring HIV (10, 20, 29, 32). These
disappointing findings suggest that there is a need for more
appropriate in vitro assays to predict in vivo safety issues.
Several in vitro and ex vivo models are currently being ex-
plored (5, 11, 13, 15, 19, 22, 27, 34). In vitro assays have the
advantage that they are quick and sensitive and can be used for
high-throughput screening in early discovery and development.
Unfortunately, until now, it has been very difficult to state
which in vitro assay best predicts in vivo toxicity. The microbi-
cides that failed in phase IIB/III trials were considered safe in
preliminary short-term phase I safety trials and had shown
activity against HIV-1 in vitro and sometimes even in macaque
models (24, 26, 36, 37). Nevertheless, they resulted in either no
benefit or possibly increased HIV-1 infection during the phase
IIB/III clinical trials. In the case of the CS phase I safety trial,
the gel was found to be safe for vaginal use (36). However, the
subsequent phase III trial was closed prematurely due to a
nonsignificantly higher incidence of HIV infections in the
treated arm than in the placebo arm (20). To date, it is unclear
whether or not the failure of CS in the clinical trial was a result
FIG. 3. Patterns of IL-8 release into basal chamber culture supernatants of HEC-1A epithelial cells cultured in Transwell inserts and treated
for 24 h with various doses of APIs or excipients. (A) APIs; (B) preservatives; (C) cosolvents; (D) surfactants; (E) cyclodextrins. IL-8 secretion
into culture basal medium is expressed as a percentage of the level of secretion for an untreated control (100%). The mean baseline level of IL-8
production of the untreated control wells was 38 pg/ml (95% confidence interval, between 31 and 46 pg/ml). Mean relative levels of secretion and
standard deviations are shown. The experiment was performed in duplicate wells.
VOL. 54, 2010 SAFETY OF CANDIDATE MICROBICIDES AND EXCIPIENTS 5111
of the lack of activity in vivo or enhancement of HIV trans-
mission. Subsequent in vitro research revealed that CS disrupts
epithelial tight junctions, resulting in the enhancement of HIV
transmission at concentrations lower than those used in the
clinical trial (27). This raises the question whether the evalu-
ations performed in phase I clinical trials are sensitive enough
to predict the safety outcomes for microbicides.
Here, we report the successful elaboration of an in vitro
dual-chamber Transwell model as a tool for rapid screening for
epithelial toxicity. In this model, epithelial cell viability was
assessed using a colorimetric assay (the WST-1 assay). Epithe-
lial layer integrity was determined by measuring the diffusion
of 0.1-m-diameter sulfate microspheres (FluoSpheres), pro-
viding a useful noninfectious alternative as a means to assess
epithelial barrier function toward HIV (15). Various microbi-
cide candidates (N-9, TMC-120, UC-781, PMPA, PRO-2000,
and GML) and excipients were tested in these assays, and
toxicity profiles were generated.
As expected, nonoxynol-9 caused epithelial layer disruption
and induced inflammation at doses used in clinical trials (3, 12,
21, 35); the present data are also consistent with previous in
vitro results (13). The reverse transcriptase inhibitors (RTIs)
PMPA, UC-781, and TMC-120 showed seemingly high selec-
tivity indices. These observations are in line with those de-
scribed in previous reports showing similarly high selectivity
indices for PMPA, TMC-120, and UC-781 in other simple in
vitro models of cell toxicity (13, 34, 38). Nevertheless, at higher
(M) concentrations, both TMC-120 and UC-781 induced
some IL-8 production. Moreover, at present it is not yet clear
what the in vivo active concentrations of these RTIs will be
when they are used as microbicides, and hence, their real
selectivity indices remain unknown. Furthermore, the polyan-
ionic entry inhibitor PRO-2000 had a less promising safety
profile. It interfered with epithelial layer integrity and induced
IL-8 secretion at concentrations that are only about 10-fold
higher than the in vitro EC50s. In contrast to the present results
for PRO-2000, Weber et al. have shown a high selectivity index
for PRO-2000, with an EC50 of 54 mg/ml and a CC50 higher
than 105 being obtained for lymphoblastoid (C8166) cells (41).
More similar to our data, Teleshova et al. showed that PRO-
2000 was not cytotoxic toward dendritic cells or CD4 T cells
at the highest concentration tested (20 M) (33), whereas it
had an EC50 of 5.8 M in cervical tissue explants (14). Next,
GML provided promising results in a simian immunodefi-
ciency virus-macaque model, inhibiting a mucosal signaling
pathway that resulted in the protection of rhesus macaques
from simian immunodeficiency virus infection. We confirmed
that GML does not induce proinflammatory IL-8, but it caused
cell death and disruption of the epithelial barrier at concen-
trations near its active in vivo concentration.
It is clear from previous prevention studies that modifica-
tions in formulations, including changes to the presumably
inactive ingredients used, can alter the efficacy and/or toxicity
of a vaginal preparation (18). Therefore, in our toxicity assays
we assessed the toxicity profiles of individual excipients belong-
ing to different classes. This would allow formulation scientists
to choose the most appropriate excipients. As various excipi-
ents belonging to various classes are added to a formulation,
the present toxicity data may constitute useful guidance to
select the most promising excipients displaying the least toxic-
ity in vitro (i.e., a typical concentration below the CC50).
Various excipients decreased viability and/or the epithelial
layer integrity of HEC-1A cells at concentration levels that
may be used in pharmaceutical preparations. Within each class
of excipients, a ranking of the toxicity of the excipients could be
made. This high level of toxicity observed with the excipients
raises the question whether the used models are not too sen-
sitive compared to the in vivo situation. The absence of an in
vivo “gold standard” for safety testing precludes the evaluation
of the biorelevance of the present model. However, as already
mentioned, the results of API testing suggest that the sensitiv-
ity of our model is similar to the sensitivities of other conven-
tional in vitro systems (i.e., CC50 values are in the same range)
(13, 34, 38). Moreover, comparing values obtained in the var-
ious viability assays, the CC50 values obtained in the cervical
explant model, which was used for comparative reasons, were
between the values obtained in the nonpolarized and the po-
larized exposure setups with HEC-1A cells.
Significant correlations were found between the data ob-
tained in the various assays. This implies that the different
assays do not generate independent data, although the sensitivi-
ties can differ. Therefore, we suggest the use of the simplest assay
(nonpolarized exposure) for a first high-throughput screening of
candidate compounds. Promising compounds could then be con-
firmed in a more relevant model, such as the dual-chamber
model.
Discrepancies between in vitro findings (e.g., our results with
PRO-2000) and the results of the clinical trials (e.g., the results
of the phase I trial with PRO-2000) may be due to various
factors. On the one hand, the settings of preclinical testing and
clinical trials are different in terms of the microbicide concen-
tration and length of exposure to the microbicides used. On the
other hand, the end points of clinical safety trials are different
and include histopathologic/microbiologic measures, the in-
flammation of the genital mucosa assessed, and the impact on
the vaginal pH and microflora determined. Moreover, epithe-
lial layer permeability, which is an important parameter re-
flecting the barrier function of the epithelium against HIV
(15), is not assessed in human safety trials. The sensitivity to
detect possible changes in cell viability and epithelial layer
integrity using colposcopy is low due to the regeneration ca-
pacity of the epithelium and the microflora. However, small
transient changes that are undetectable by colposcopy could
already increase the susceptibility to HIV. Therefore, as long
as there is no certainty about the in vivo standard for safety
assessment, potential safety issues detected in in vitro/ex vivo
assays should be seriously considered. The international efforts
to identify vaginal biomarkers, including cytokines and chemo-
kines, are the way forward to correlate in vitro and in vivo
safety testing more properly.
In this context, a correlation between mucosal toxicity and
increased levels of the proinflammatory chemokine IL-8 in
vaginal washings of spermicide-treated rabbits has been ob-
served (12). The significant increase of IL-8 observed upon
treatment with noncytotoxic concentrations of some APIs and
excipients might result in an increased susceptibility to HIV
infection in vivo, because IL-8 might attract HIV target cells.
Therefore, assessment of IL-8 might be used as a sensitive
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assay complementary to the existing in vitro toxicity and epi-
thelial layer integrity assays.
Recently, Rohan et al. showed that a tenofovir gel and a
placebo gel composed of hydroxyethycellulose, EDTA, citric
acid, glycerin, and the preservatives methyl- and propylpara-
ben were detrimental toward epithelial cells and explants,
causing a reduced viability and epithelial layer integrity of
HEC-1A and Caco-2 cells and cervical tissue explants (30).
Similar observations were made by Dezzutti et al., assessing
the toxicity and epithelial layer integrity of HEC-1A and
Caco-2 cell lines after exposure to PRO-2000 gel, UC-781 gel,
and the placebo gels methylcellulose and Vena Gel (7). More-
over, even higher levels of toxicity were observed with KY jelly
placebo gel than with Vena Gel. These data are in line with our
data and suggest safety issues with the use of certain placebo
gels/pharmaceutical excipients.
In the present study, various cell lines that originate from the
upper and lower female genital tract were used, and only slight
differences in sensitivity were observed, although the CaSki cell
line forms a monolayer, whereas HEC-1A and SiHa cells tend
to form stratified epithelia with a thickness of 4 to 5 cell layers
(15). The HEC-1A cell model might therefore not be very
representative of the uterine (or endocervical) epithelia, which
are monolayers, but rather might represent an intermediate
between the endo- and ectocervical epithelia. Although it is
possible that the toxicity tested in a model of truly multistrati-
fied epithelium may be lower, APIs and excipients should not
be deleterious toward single-layered epithelia. In fact, ectopy,
a condition which is characterized by the extension of endo-
cervical single-layered columnar epithelium over the ectocer-
vix, is a frequently occurring nonpathological condition present
in adolescent women around the menarche, during pregnancy,
and postpartum. Because young women are most vulnerable
for HIV infection, an effective microbicide designed to prevent
the further spread of HIV, especially in Africa, should be
tailored to this specific population (25, 28). Therefore, each
product (API or excipient) that causes the slightest damage to
this ectopic endocervix is unwanted.
In summary, a high-throughput dual-chamber model has
been evaluated for microbicide safety testing. Surprisingly, cell
viability and epithelial layer integrity were compromised by
most excipients at concentrations near the typically used con-
centration. A toxicity ranking of the excipients was made
within each class. IL-8 was induced by several excipients at
subtoxic concentrations, suggesting that even low concentra-
tions of some compounds may induce a proinflammatory en-
vironment. Among the active ingredients, UC-781 and PMPA
showed no toxicity and almost no induction of IL-8 at the
tested concentrations, whereas TMC-120, PRO-2000, GML,
and N-9 showed some toxic effects and/or induced IL-8 secre-
tion. Early identification of safety issues concerning the use of
pharmaceutical excipients should reduce the risk of toxicity
failure in animal and clinical testing of microbicide prepara-
tions.
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